Literature DB >> 10521429

Cloning the promoter for transforming growth factor-beta type III receptor. Basal and conditional expression in fetal rat osteoblasts.

C Ji1, Y Chen, T L McCarthy, M Centrella.   

Abstract

Transforming growth factor-beta binds to three high affinity cell surface molecules that directly or indirectly regulate its biological effects. The type III receptor (TRIII) is a proteoglycan that lacks significant intracellular signaling or enzymatic motifs but may facilitate transforming growth factor-beta binding to other receptors, stabilize multimeric receptor complexes, or segregate growth factor from activating receptors. Because various agents or events that regulate osteoblast function rapidly modulate TRIII expression, we cloned the 5' region of the rat TRIII gene to assess possible control elements. DNA fragments from this region directed high reporter gene expression in osteoblasts. Sequencing showed no consensus TATA or CCAAT boxes, whereas several nuclear factors binding sequences within the 3' region of the promoter co-mapped with multiple transcription initiation sites, DNase I footprints, gel mobility shift analysis, or loss of activity by deletion or mutation. An upstream enhancer was evident 5' proximal to nucleotide -979, and a silencer region occurred between nucleotides -2014 and -2194. Glucocorticoid sensitivity mapped between nucleotides -687 and -253, whereas bone morphogenetic protein 2 sensitivity co-mapped within the silencer region. Thus, the TRIII promoter contains cooperative basal elements and dispersed growth factor- and hormone-sensitive regulatory regions that can control TRIII expression by osteoblasts.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Substances:

Year:  1999        PMID: 10521429     DOI: 10.1074/jbc.274.43.30487

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Impact of mechanical stretch on the cell behaviors of bone and surrounding tissues.

Authors:  Hye-Sun Yu; Jung-Ju Kim; Hae-Won Kim; Mark P Lewis; Ivan Wall
Journal:  J Tissue Eng       Date:  2015-12-29       Impact factor: 7.813

Review 2.  Roles for the type III TGF-beta receptor in human cancer.

Authors:  Catherine E Gatza; Sun Young Oh; Gerard C Blobe
Journal:  Cell Signal       Date:  2010-02-12       Impact factor: 4.315

3.  The type III TGF-beta receptor suppresses breast cancer progression.

Authors:  Mei Dong; Tam How; Kellye C Kirkbride; Kelly J Gordon; Jason D Lee; Nadine Hempel; Patrick Kelly; Benjamin J Moeller; Jeffrey R Marks; Gerard C Blobe
Journal:  J Clin Invest       Date:  2006-12-07       Impact factor: 14.808

4.  Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Authors:  Nadine Hempel; Tam How; Simon J Cooper; Tyler R Green; Mei Dong; John A Copland; Christopher G Wood; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

5.  Novel links among Wnt and TGF-beta signaling and Runx2.

Authors:  Thomas L McCarthy; Michael Centrella
Journal:  Mol Endocrinol       Date:  2010-01-21

6.  Repression of myoblast proliferation and fibroblast growth factor receptor 1 promoter activity by KLF10 protein.

Authors:  Rajini Parakati; Joseph X DiMario
Journal:  J Biol Chem       Date:  2013-04-08       Impact factor: 5.157

7.  Overexpression of transforming growth factor type III receptor restores TGF-β1 sensitivity in human tongue squamous cell carcinoma cells.

Authors:  Duo Li; Dongyang Xu; Zhiyong Lu; Xingli Dong; Xiaofeng Wang
Journal:  Biosci Rep       Date:  2015-07-23       Impact factor: 3.840

8.  TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.

Authors:  Keren Tazat; Melissa Hector-Greene; Gerard C Blobe; Yoav I Henis
Journal:  Mol Biol Cell       Date:  2015-08-12       Impact factor: 4.138

Review 9.  Impact of mechanical stretch on the cell behaviors of bone and surrounding tissues.

Authors:  Hye-Sun Yu; Jung-Ju Kim; Hae-Won Kim; Mark P Lewis; Ivan Wall
Journal:  J Tissue Eng       Date:  2016-02-13       Impact factor: 7.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.